Skip to main content
PolyPeptide Group AG logo

PolyPeptide Group AG — Investor Relations & Filings

Ticker · PPGN ISIN · CH1110760852 LEI · 5067007JCKTPOX4G9758 SW Manufacturing
Open in API
Filings indexed 111 across all filing types
Latest filing 2025-12-12 Regulatory Filings
Country CH Switzerland
Listing SW PPGN

About PolyPeptide Group AG

https://www.polypeptide.com/

PolyPeptide Group AG is a Contract Development & Manufacturing Organization (CDMO) specializing in peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs). The company serves the pharmaceutical and biotech sectors by providing a comprehensive range of services that cover all stages of product development, from pre-clinical to commercial manufacturing. Its offerings include both proprietary (custom) and generic GMP-grade peptides. PolyPeptide focuses on innovation in peptide synthesis and manufacturing processes to support the development of therapies for patients.

Recent filings

Filing Released Lang Actions
PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet Growing Demand for Peptide Supply in Metabolic Therapies
Regulatory Filings Classification · 95% confidence The document is a media release announcing a strategic alliance between PolyPeptide Group and Lupin Manufacturing Solutions. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a board change or legal proceeding. As it is a general corporate announcement regarding business operations and partnerships, it falls under the 'Regulatory Filings' (RNS) category, which serves as the fallback for miscellaneous corporate news and regulatory announcements.
2025-12-12 English
PolyPeptide Group achieves significant milestone in Malmo expansion project
Regulatory Filings Classification · 100% confidence The document is a corporate media release announcing a milestone in a facility expansion project (Malmö). It does not report financial results, board changes, or regulatory filings, but rather provides a general corporate update regarding operational progress. As it does not fit into specific categories like earnings, dividends, or governance, it falls under the general regulatory announcement category.
2025-09-22 English
PolyPeptide Group achieves significant milestone in Malmö expansion project
Regulatory Filings Classification · 100% confidence The document is a media release issued by PolyPeptide Group regarding a milestone in their Malmö expansion project. It provides operational updates, strategic context, and project highlights. It does not fit into specific financial reporting categories like 10-K, ER, or IR, nor is it a simple announcement of a report (RPA). As it is a general corporate announcement regarding business operations and expansion, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2025-09-22 English
PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian site, 2025 full-year guidance revised towards the upper end of the range
Earnings Release Classification · 100% confidence The document is an 'ad-hoc announcement' regarding PolyPeptide's H1 2025 financial results. It provides key highlights, financial tables, management commentary, and guidance updates. Crucially, it explicitly states that the full 'Half-Year Report 2025' is available via a link, confirming this document is the initial earnings release (summary) rather than the full report itself. Therefore, it fits the definition of an Earnings Release (ER). H1 2025
2025-08-12 English
PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian site, 2025 full-year guidance revised towards the upper end of the range
Earnings Release Classification · 100% confidence The document is an 'ad hoc announcement' detailing the H1 2025 financial results for PolyPeptide Group. It provides key performance indicators (revenue, EBITDA, cash flow), management commentary, and guidance updates. While it mentions the availability of a full 'Half-Year Report 2025' via a link, the document itself contains the core financial highlights and management's analysis of the period, which is characteristic of an Earnings Release (ER). It is not merely a notification of a report's existence (RPA) because it provides substantial financial data and analysis directly in the text. H1 2025
2025-08-12 English
PolyPeptide wächst im ersten Halbjahr 2025 um 24%, mit einer erfolgreichen Anlaufphase am belgischen Standort – Jahresprognose wird innerhalb der Guidance nach oben angepasst
Interim / Quarterly Report Classification · 95% confidence The document is an 'Ad hoc-Mitteilung' (Ad-hoc announcement) from PolyPeptide Group regarding their H1 2025 financial results. It contains detailed financial tables, management commentary, and performance analysis for the interim period. While it is an announcement, it provides substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR) rather than just a brief publication notice. H1 2025
2025-08-12 German

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.